Moreover, activators of FAO, like bezafibrate, could potentiate anti-PD-1 therapy by inducing the expression of CXCL9 and CXCL10 from tumor cells and CXCR3 on intra-tumor effector T cells (187, 188). This evidence concerns the gene CXCL9 and neoplasm.